Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report
Oral decitabine/cedazuridine has been studied in chronic myelomonocytic leukemia (CMML) recently but the molecular changes during this treatment have not been reported so far. We report a CMML patient who was treated with oral decitabine/cedazuridine and showed a stepwise loss of KRAS mutation and trisomy 8 while the TET2 mutated clone gradually increased eventually resulting in clonal hematopoiesis. This case report highlights the disease modifying potential of this treatment in single CMML patients.
Authors
- Roland Jäger (ORCID: https://orcid.org/0000-0003-4530-1344)
- Gerlinde Mitterbauer-Hohendanner
- Klaus Geissler
Institutions
- Sigmund Freud Privatuniversität Wien (AT)
- Karl Landsteiner University of Health Sciences (AT)
- Karl Landsteiner Society (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Annals of Hematology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1007/s00277-026-06850-3
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00